# US 12,178,904 B2 · Contact lenses including medicaments and methods of making and using same including stabilizers of labile components such as drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,904 B2
- Document ID: US12178904B2
- Status: Granted
- Kind: B2
- Application number: 18/606,551
- Filed: 2024-03-15
- Published: 2024-08-29
- Granted: 2024-12-31
- Earliest claimed: 2022-07-15
- Applicants: Mediprint Ophthalmics Inc.
- Inventors: Praful Doshi; Brandon Huang; Stephen Halbe; Neil Patodia; Pavanasam Natarajan Balasubramanian
- Web page: https://patentgrep.com/patent/US12178904B2

## CPC

- A61K 9/0051: {Ocular inserts or implants}
- G02B 1/043: {Contact lenses}
- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 47/40: Cyclodextrins; Derivatives thereof
- B29D 11/00096: {for delivering compositions, e.g. drugs to the eye}
- B29D 11/00865: {Applying coatings; tinting; colouring (printing, marking or copying processes B41M; identification in general G09F3/00; producing decorative effects in general B44C; positioning or marking of lenses B24B13/0055)}
- G02C 7/04: Contact lenses for the eyes (disinfection or sterilisation of contact lenses A61L12/00)
- G02C 7/049: {Contact lenses having special fitting or structural features achieved by special materials or material structures}
- A61L 2/07: Steam
- G02C 2202/24: Myopia progression prevention
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G02B: OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- B29D: PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE (making granules B29B9/00; making preforms B29B11/00)
- G02C: SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES (trial frames for testing the eyes A61B3/04; goggles or eyeshields not having the same features as spectacles A61F9/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having at least one coating made at least in part using printing technologies to provide drug storage and drug release structures, notably for hydrophobic drugs and that such hydrophobic drugs can be stabilized as to hydrolysis, heat, and a combination thereof. A first aspect of the present invention includes a packaged medical device that includes at least one drug delivery contact lens. A second aspect of the present invention includes a drug delivery contact lens. A third aspect of the present invention includes a method of making a drug delivery contact lens. A fourth aspect of the present invention includes an ink. A fifth aspect of the present invention includes a method of using a drug delivery contact lens to treat or prevent a disease, disorder, or condition of the eye.

## Claims

### Claim 1

A packaged medical device, comprising:
a) at least one drug delivery contact lens, comprising:
i) at least one coating provided on at least one surface of said drug delivery contact lens;
where said at least one coating comprises at least one emulsion;
ii) at least one hydrophobic drug;
wherein said at least one hydrophobic drug comprises at least one prostaglandin, at least one prostaglandin derivative, or a combination thereof;
wherein said at least one coating comprises said at least one hydrophobic drug;
wherein said at least one hydrophobic drug is subject to degradation by hydrolysis;
further wherein said at least one hydrophobic drug is incorporated into at least one emulsion;
b) at least one packaging solution, comprising:
1) said at least one hydrophobic drug;
2) at least one emulsion;
c) at least one packaging, comprising:
1) said at least one drug delivery contact lens; and
2) said at least one packaging solution;
d) further wherein said at least one hydrophobic drug is stabilized against hydrolysis in said at least one drug delivery contact lens, in said at least one packaging solution, or a combination thereof, under conditions of steam sterilization, heat, or a combination thereof, at temperatures of up to 100° C. or above.

### Claim 2 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one coating is made in whole or in part by additive printing.

### Claim 3 (depends on 2)

The packaged medical device of claim 2;
wherein said additive printing comprises ink jet printing.

### Claim 4 (depends on 2)

The packaged medical device of claim 2;
wherein said additive printing comprises digital printing, 3D printing, digital 3D printing, pad printing, or a combination thereof.

### Claim 5 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one hydrophobic drug comprises latanoprost, or bimatoprost, or combinations thereof.

### Claim 6 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one hydrophobic drug comprises latanoprost.

### Claim 7 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one hydrophobic drug is stabilized by said at least one emulsion, against hydrolysis in said drug delivery contact lens, or in said packaged medical device, or said at least one coating, or said at least one packaging solution, or combinations thereof.

### Claim 8 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one emulsion comprises at least one microemulsion.

### Claim 9 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one emulsion comprises at least one oil-in water emulsion, at least one oil-in water microemulsion, or a combination thereof.

### Claim 10 (depends on 1)

The packaged medical device of claim 1;
wherein said drug delivery contact lens comprises:
a) a soft contact lens;
b) a multifocal contact lens; or
c) a combination thereof.

### Claim 11 (depends on 1)

The packaged medical device of claim 1;
wherein release of said at least one hydrophobic drug from said at least one drug delivery contact lens is modulated by the physical properties of said at least one drug delivery lens, the chemical properties of said at least one drug delivery lens, or a combination thereof.

### Claim 12 (depends on 11)

The packaged medical device of claim 11;
wherein said physical properties of said drug delivery lens comprise structures or conditions provided by said additive printing, or a combination thereof.

### Claim 13 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one coating comprises one or more layers.

### Claim 14 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one hydrophobic drug is provided in a pharmaceutically effective amount.

### Claim 15 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one hydrophobic drug is heat labile.

### Claim 16 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one hydrophobic drug in said at least one drug delivery contact lens, in said at least one packaging solution, or a combination thereof, is steam stabilized, heat stabilized, hydrolysis stabilized, or a combination thereof.

### Claim 17 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one emulsion comprises oil droplets in a water medium to form at least one emulsion, at least one microemulsion, or a combination thereof.

### Claim 18 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one packaging comprises at least one blister pack.

### Claim 19 (depends on 1)

The packaged medical device of claim 1;
wherein said at least one packaging comprises at least one vial.

### Claim 20 (depends on 1)

The packaged medical device of claim 1;
wherein said packaged medical device, said at least one drug delivery contact lens, said at least one packaging solution, or a combination thereof, comprise at least one additional drug.

### Claim 21 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug is provided in a pharmaceutically effective amount.

### Claim 22 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug comprises at least one hydrophilic drug.

### Claim 23 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug further comprises at least one hydrophobic drug.

### Claim 24 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug is selected from the group consisting of an antibiotic, an intraocular pressure reducing agent, a comfort enhancing agent, an anti-inflammatory agent, a penetration enhancer, a macular degeneration agent, a diabetic retinopathy agent, and combinations thereof.

### Claim 25 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug further comprises dorzolamide, timolol, or a combination thereof.

### Claim 26 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug is selected from the group consisting of timolol, alphagan, axopt, cosopt, lumigan, travatan, xalatan, combigan, timolol hemihydrate, betaxolol, levobunolol, metipranolol, apraclonidine, Brimonidine tartate, Brinzolamide, methazolamide, dorzolamide, acetazolamide, carbachol, travoprost, latanoprostene bunod, tafluprost, netarsudil, and combinations thereof.

### Claim 27 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug is selected from the group consisting of sodium hyaluronate, hyaluronic acid, cyclosporine, polyethylene glycol 400, hypromellose, polyvinyl alcohol, carboxymethylcellulose, dextran 70, hydroxypropyl methylcellulose, anhydrous liquid lanolin, mineral oil, white petroleum, mannitol, thiomersal, carbomer, cetrimide, glycerin, polysorbate80, povidone, and combinations thereof.

### Claim 28 (depends on 20)

The packaged medical device of claim 20; wherein said at least one additional drug is selected from the group consisting of perdforte, lotemax, fluromethlone, nevanac, acular, xibrom, and combinations thereof.

### Claim 29 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug is selected from the group consisting of Flurbiprofen, Acetazolamide, ethylenediaminetetraacetic acid, palmitoyl carnitine, sodium caprate, sodium dodecylsulphate, sodium deoxycholate, poly oxyethylene-g-lauryl ether, 1-α-lysophosphatidylocholine, deoxycholate, taurodeoxycholate, glycocholate, benzalkonium chloride, and combinations thereof.

### Claim 30 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug comprises aflibercept.

### Claim 31 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug is selected from the group consisting of dexamethasone, at least one steroid, pilocarpine nitrate, tropicamide, methyl prednisolone, flurbiprofen, penicillin, ciprofloxacin, sulphacetaminde sodium, indomethacin, hydrocortisone, indomethacin, ciprofloxacin hydrochloride, insulin, indomethacin, ketorolac tromethamine, and combinations thereof.

### Claim 32 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug is selected from the group consisting of gentamicin, tobramycin, erythromycin, polytrim, cirproflizacin, viamox, xymar, and combinations thereof.

### Claim 33

A drug delivery contact lens, comprising:
a) coating provided on at least one surface of said drug delivery contact lens;
where said at least one coating comprises at least one emulsion;
b) at least one hydrophobic drug;
wherein said at least one hydrophobic drug comprises at least one prostaglandin, at least one prostaglandin derivative, or a combination thereof;
wherein said at least one coating comprises said at least one hydrophobic drug;
wherein said at least one hydrophobic drug is subject to degradation by hydrolysis;
further wherein said at least one hydrophobic drug is incorporated into at least one emulsion,
further wherein said at least one hydrophobic drug is stabilized against hydrolysis in said drug delivery contact lens under conditions of steam sterilization, heat, or a combination thereof, at temperatures of up to 100° C., or above.

### Claim 34 (depends on 33)

The drug delivery contact lens of claim 33;
wherein said at least one coating is made in whole or in part by additive printing.

### Claim 35 (depends on 34)

The drug delivery contact lens of claim 34;
wherein said additive printing comprises ink jet printing.

### Claim 36 (depends on 34)

The drug delivery contact lens of claim 34;
wherein said additive printing comprises digital printing, 3D printing, digital 3D printing, pad printing, or a combination thereof.

### Claim 37 (depends on 33)

The packaged medical device of claim 33;
wherein said at least one hydrophobic drug comprises latanoprost, bimatoprost, or a combination thereof.

### Claim 38 (depends on 33)

The packaged medical device of claim 33;
wherein said at least one hydrophobic drug comprises latanoprost.

### Claim 39 (depends on 33)

The packaged medical device of claim 33; wherein said hydrophobic drug is stabilized by said at least one emulsion, against hydrolysis in said drug delivery contact lens, or in said packaged medical device, or said at least one coating, or said at least one packaging solution, or combinations thereof.

### Claim 40 (depends on 33)

The drug delivery contact lens of claim 33;
wherein said at least one emulsion comprises at least one microemulsion.

### Claim 41 (depends on 33)

The drug delivery contact lens of claim 33;
wherein said at least one emulsion comprises at least one oil-in water emulsion, at least one oil-in water microemulsion, or a combination thereof.

### Claim 42 (depends on 33)

The drug delivery contact lens of claim 33;
wherein said drug delivery contact lens comprises:
a) a soft contact lens;
b) a multifocal contact lens; or
c) a combination thereof.

### Claim 43 (depends on 33)

The drug delivery contact lens of claim 33;
wherein the release of said at least one hydrophobic drug from said drug delivery contact lens is modulated by the physical properties of said drug delivery lens, the chemical properties of said drug delivery lens, or a combination thereof.

### Claim 44 (depends on 43)

The drug delivery contact lens of claim 43;
wherein said physical properties of said drug delivery lens comprise structures or conditions provided by said additive printing, or a combination thereof.

### Claim 45 (depends on 33)

The drug delivery contact lens of claim 33;
wherein said at least one coating comprises one or more layers.

### Claim 46 (depends on 33)

The drug delivery contact lens of claim 33;
wherein said at least one hydrophobic drug is provided in a pharmaceutically effective amount.

### Claim 47 (depends on 33)

The drug delivery contat lens of claim 33;
wherein said at least one hydrophobic drug is heat labile.

### Claim 48 (depends on 33)

The drug delivery contact lens of claim 33;
wherein said at least one emulsion comprises oil droplets in a water medium to form at least one emulsion, at least one microemulsion, or a combination thereof.

### Claim 49 (depends on 33)

The drug delivery contact lens of claim 33;
wherein said drug delivery contact lens comprises at least one additional drug.

### Claim 50 (depends on 49)

The drug delivery contact lens of claim 49;
wherein said at least one additional drug is provided in a pharmaceutically effective amount.

### Claim 51 (depends on 49)

The drug delivery contact lens of claim 49;
wherein said at least one additional drug comprises at least one hydrophilic drug.

### Claim 52 (depends on 49)

The drug delivery contact lens of claim 49;
wherein said at least one additional drug comprises at least one hydrophobic drug.

### Claim 53 (depends on 49)

The drug delivery contact lens of claim 49;
wherein said at least one additional drug comprises an antibiotic, an intraocular pressure reducing agent, a comfort enhancing agent, an anti-inflammatory agent, a penetration enhancer, a macular degeneration agent, diabatic retinopathy agent, or a combination thereof.

### Claim 54 (depends on 1)

A method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof, the method comprising;
a) providing at least one packaged medical device of claim 1;
b) providing a subject in need of treatment of at least one disease, or disorder, or condition of an eye of said subject, by said at least one drug in at least one drug delivery contact lens;
c) operably engaging said at least one drug delivery contact lens on an eye of said subject;
d) wherein said subject is treated for said at least one disease, or disorder, or condition of an eye of said subject, by said at least one drug in said at least one drug delivery contact lens.

### Claim 55 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said disease, disorder, or condition of the eye comprises
a) glaucoma;
b) myopia; or
c) a combination thereof.

### Claim 56 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one coating is made in whole or in part by additive printing.

### Claim 57 (depends on 56)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 56;
wherein said additive printing comprises ink jet printing.

### Claim 58 (depends on 56)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 56;
wherein said additive printing comprises digital printing, 3D printing, digital 3D printing, pad printing, or combinations thereof.

### Claim 59 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one hydrophobic drug comprises latanoprost, bimatoprost, or combinations thereof.

### Claim 60 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one hydrophobic drug comprises latanoprost.

### Claim 61 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one hydrophobic drug is stabilized by said at least one emulsion, against hydrolysis in said drug delivery contact lens, or in said packaged medical device, or said at least one coating, or said at least one packaging solution, or combinations thereof.

### Claim 62 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one emulsion comprises at least one microemulsion.

### Claim 63 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one emulsion comprises at least one oil-in water emulsion, at least one oil-in water microemulsion, or a combination thereof.

### Claim 64 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said drug delivery contact lens comprises:
a) a soft contact lens;
b) a multifocal contact lens; or
c) a combination thereof.

### Claim 65 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein release of said at least one hydrophobic drug from said drug delivery contact lens is modulated by the physical properties of said drug delivery contact lens, the chemical properties of said drug contact delivery lens, or a combination thereof.

### Claim 66 (depends on 65)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 65;
wherein said physical properties of said drug delivery lens comprise structures or conditions provided by said additive printing, or a combination thereof.

### Claim 67 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one coating comprises one or more layers.

### Claim 68 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one hydrophobic drug is provided in a pharmaceutically effective amount.

### Claim 69 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one hydrophobic drug is heat labile.

### Claim 70 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one hydrophobic drug in said drug delivery contact lens, in said at least one packaging solution, or a combination thereof, is steam stabilized, or heat stabilized, or hydrolysis stabilized, or a combinations thereof.

### Claim 71 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one emulsion comprises oil droplets in a water medium to form at least one emulsion, at least one microemulsion, or a combination thereof.

### Claim 72 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one packaging comprises at least one blister pack.

### Claim 73 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one packaging comprises at least one vial.

### Claim 74 (depends on 54)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 54;
wherein said at least one packaged medical device, said at least one drug delivery contact lens, said at least one packaging solution, or combinations thereof, comprise at least one additional drug.

### Claim 75 (depends on 74)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 74;
wherein said at least one additional drug is provided in a pharmaceutically effective amount.

### Claim 76 (depends on 74)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 74;
wherein said at least one additional drug comprises at least one hydrophilic drug.

### Claim 77 (depends on 74)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 74;
wherein said at least one additional drug comprises at least one hydrophobic drug.

### Claim 78 (depends on 74)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 74;
wherein said at least one additional drug comprises an antibiotic, an intraocular pressure reducing agent, a comfort enhancing agent, an anti-inflammatory agent, a penetration enhancer, a macular degeneration agent, diabatic retinopathy agent, or combinations thereof.

### Claim 79 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug comprises at least one cannabinoid.

### Claim 80 (depends on 79)

The packaged medical device of claim 79;
wherein said at least one cannabinoid is selected from the group consisting of tetrahydrocannabinoid (THC), 2-Arachidonoylglycerol (2-AG), N-arachidonoylethanolamine (AEA), delta-9-thc, delta-8-THC, (R)-(+)-[2,3-Dihydro-5-methyl-3 [(4-morpholinyl) methyl] pyrrolo [1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate salt (WIN 55,212-2), and combinations thereof.

### Claim 81 (depends on 20)

The packaged medical device of claim 20;
wherein said at least one additional drug comprises at least one cannabinoid that can treat glaucoma.

### Claim 82 (depends on 81)

The packaged medical device of claim 81,
wherein said at least one cannabinoid is selected from the group consisting of etrahydrocannabinoid (THC), 2-Arachidonoylglycerol (2-AG), N-arachidonoylethanolamine (AEA), delta-9-thc, delta-8-THC, (R)-(+)-[2,3-Dihydro-5-methyl-3 [(4-morpholinyl) methyl] pyrrolo [1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone (WIN 55,212-2), and combinations thereof.

### Claim 83 (depends on 49)

The drug delivery contact lens of claim 49;
wherein said at least one additional drug comprises at least one cannabinoid.

### Claim 84 (depends on 83)

The drug delivery contact lens of claim 83;
wherein said at least one cannabinoid is selected from the group consisting of tetrahydrocannabinoid (THC), 2-Arachidonoylglycerol (2-AG), N-arachidonoylethanolamine (AEA), delta-9-thc, delta-8-THC, (R)-(+)-[2,3-Dihydro-5-methyl-3 [(4-morpholinyl) methyl] pyrrolo [1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone (WIN 55,212-2), and combinations thereof.

### Claim 85 (depends on 49)

The packaged medical device of claim 49;
wherein said at least one additional drug comprises at least one cannabinoid that can treat glaucoma.

### Claim 86 (depends on 85)

The drug delivery contact lens of claim 85;
wherein said at least one cannabinoid is selected from the group consisting of tetrahydrocannabinoid (THC), 2-Arachidonoylglycerol (2-AG), N-arachidonoylethanolamine (AEA), delta-9-thc, delta-8-THC, (R)-(+)-[2,3-Dihydro-5-methyl-3 [(4-morpholinyl) methyl] pyrrolo [1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone (WIN 55,212-2), and combinations thereof.

### Claim 87 (depends on 74)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 74;
wherein said at least one additional drug comprises at least one cannabinoid.

### Claim 88 (depends on 87)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 87;
wherein said at least one cannabinoid is selected from the group consisting of tetrahydrocannabinoid (THC), 2-Arachidonoylglycerol (2-AG), N-arachidonoylethanolamine (AEA), delta-9-thc, delta-8-THC, (R)-(+)-[2,3-Dihydro-5-methyl-3 [(4-morpholinyl) methyl] pyrrolo [1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone (WIN 55,212-2), and combinations thereof.

### Claim 89 (depends on 74)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 74;
wherein said at least one additional drug is comprises at least one cannabinoid that can treat glaucoma.

### Claim 90 (depends on 89)

The method of treating at least one disease, or disorder, or condition of an eye of a subject in need of treatment thereof of claim 89;
wherein said at least one cannabinoid is selected from the group consisting of tetrahydrocannabinoid (THC), 2-Arachidonoylglycerol (2-AG), N-arachidonoylethanolamine (AEA), delta-9-thc, delta-8-THC, (R)-(+)-[2,3-Dihydro-5-methyl-3 [(4-morpholinyl) methyl] pyrrolo [1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone (WIN 55,212-2), and combinations thereof.